Innovation in Genetic Medicines

We develop precision nucleic acid therapies addressing key clinical unmet needs through strategic development partnerships.

Pipeline/Partnership
Oncology
COVID-19
Age-related Diseases
Program
Partner
Discovery
Screening
Preclinical
Phase 1
Phase 2
Phase 3
Internal
Undisclosed
Undisclosed
Vaccines
8 Undisclosed programs
2 Programs: DNA vaccines and Neutralizing antibodies
OSX-002: Immuno-oncology gene therapy
OncoSenX
OSX-001: p53-targeted suicide gene therapy
OncoSenX
Atherosclerosis
Senolytic
REPAIR Biotechnologies
OISIN Biotechnologies
3 undisclosed programs
Undisclosed
Metastasis
Multiple; CIHR, DARPA, NRC IRAP
Oncology
Auto Immune
Age Related Diseases
Program/Partner
Discovery
Screening
Preclinical
P1
P2
P3
Vaccines / Undisclosed
Immuno-oncology gene therapy / Entos JV OncoSenX
p53-targeted suicide gene therapy / Entos JV OncoSenX
8 undisclosed programs / Undisclosed
Senolytic / Oisin
Undisclosed / Undisclosed
Metastasis / Internal
2 undisclosed programs / Undisclosed
Atherosclerosis / Repair Bio
Oncology
Auto Immune
Age-related Diseases
Program/Partner
Dis
Scr
Pre
P1
P2
P3
Vaccines / Undisclosed
Immuno-oncology gene therapy / Entos JV OncoSenX
p53-targeted suicide gene therapy / Entos JV OncoSenX
8 undisclosed programs / Undisclosed
Senolytic / Oisin
Undisclosed / Undisclosed
Metastasis / Internal
2 undisclosed programs / Undisclosed
Atherosclerosis / Repair Bio
Oncology
Auto Immune
Age-related Diseases
Dis
P2
P3
P1
Scr
Pre
p53-targeted suicide gene therapy / Entos JV OncoSenX
Immuno-oncology gene therapy /
Entos JV OncoSenX
Vaccines / Undisclosed
8 undisclosed programs / Undisclosed
Metastasis / Internal
Undisclosed / Undisclosed
Senolytic / Oisin
Atherosclerosis / Repair Bio
2 undisclosed programs / Undisclosed
Entos Pharmaceuticals
Unit 4550, 10230 Jasper Avenue
Edmonton, Alberta, Canada
T5J 4P6

Email: info@entospharma.com
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.